Skip to main navigation

Menu

Skip to content

Investors

Alnylam

E-mail Alerts

Download Center

Print

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter

Financial Information

FinancialMenu

Fundamentals
Financial Information
Quarterly Results
Key Ratios
Annual Reports

Here you will find a summary of Alnylam Pharmaceuticals, Inc.'s latest financial information.

Show all

Latest Earnings Release and 10-Q

First Quarter Financial Results
Form 10-Q

Show all

Latest Annual Report and 10-K

2018 Annual Report 13.8 MB
Form 10-K

Show all

Latest Proxy Statement

Latest Proxy Statement

Share Related Items

Market Capitalization (Mil)	$7,579.03
Shares Outstanding (Mil)	106.54
Shares Outstanding, Average (FY) (Mil)	100.59
Float (Mil)	105.61

Copyright Thomson Reuters Corporation

FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.

Search

Recent Press Releases

View all releases

Jun 24,2019

Summary Toggle Alnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting
Jun 21,2019

Summary Toggle Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery
Jun 18,2019

Summary Toggle Alnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

View all releases

: (Common):

Price:
Change (%):
Volume:
Data as of Copyright NASDAQ. Minimum 15 minutes delay

twitter
linkedin
youtube
rss

Copyright © 2019 Alnylam Pharmaceuticals, Inc. --- All Rights Reserved --- Glossary | Media Kit | Legal | Privacy Policy | Site Map